Company Filing History:
1 out of 32 
1 out of 3 Years Active: 2008
Title: David Witcombe: A Pioneer in Nucleic Acid Research
Introduction
David Witcombe, an accomplished inventor based in Eastwood, Australia, is renowned for his significant contributions to the field of molecular biology. He holds a remarkable patent that focuses on the development of an isolated nucleic acid with applications in vaccine development.
Latest Patents
Witcombe is the inventor of a notable patent that presents an isolated nucleic acid comprising a nucleotide sequence encoding a 250 kDa polypeptide derived from Sporozoites and Merozoites. This invention not only provides a method for producing a recombinant version of this polypeptide but also includes formulations for creating vaccines. The patent emphasizes an immunodominant portion of the 250 kDa polypeptide and includes formulations that may also contain additional proteins isolated from gametocytes. This groundbreaking work has significant potential for immunization against infectious diseases.
Career Highlights
Throughout his career, David Witcombe has worked with prestigious organizations such as the University of Technology Sydney and Abic Biological Laboratories, Teva Ltd. These roles have allowed him to collaborate with leading scientists and contribute to vital research in biotechnology and vaccine development.
Collaborations
Witcombe has collaborated with noteworthy colleagues, including Nicholas C. Smith and Michael Wallach. These partnerships have enriched his work and furthered advancements in the scientific community, particularly in the arena of vaccine research and development.
Conclusion
David Witcombe's innovative research and patent contributions underscore his role as a significant figure in the field of molecular biology. His dedication to developing therapies that combat infectious diseases positions him as a leader in the scientific realm, paving the way for future advancements in immunology.